Evolution's molecular forms of prostate-specific antigen in serological groups of patients with prostatic pathologies;Évolution des formes moléculaires de l'antigène spécifique de la prostate chez des groupes sérologiques de patients atteints de pathologies prostatiques

Immuno-Analyse et Biologie Specialisee

Volumn 21, Issue 5, 2006, Pages 286-291

  Bouraoui, Y ^a   Ben Rais, N ^b   Elouni, Z ^b   Mezigh, C ^b   Machghoul, S ^b   Oueslati, R ^a  

^a University of Carthage   (Tunisia)

^b MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Cut off value; Free PSA; Free PSA total PSA; Prostatic pathologies; Total PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEROLOGY;

EID: 33749255182     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2006.07.006     Document Type: Article

References (39)

1. American Urological Association (AUA). Prostate-specific antigen (APS) best practice policy. Oncology 14 (2000) 267-272 (277-278, 280,283-286)
2. Balk S.P., Ko Y.J., and Bubley G.J. Biology of prostate-specific antigen. J. Clin. Oncol. 21 (2003) 383-391
3. Black H.M., and Diamandis E.P. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res. Treat. 59 (2000) 1-14
4. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of the free prostate-specific antigen to enhance the differenciation of prostate cancer from begnin prostatic disease: a prosoective multicenter clinical trial. JAMA 279 (1998) 1542-1547
5. Catalona W.J., Smith S.D., Ratliff T.L., Dodds K.M., Colpen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a sceening test for prostate cancer. N. Engl. Med. 324 (1991) 1156-1161
6. Culig Z., Bartsch G., and Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 197 (2002) 231-238
7. Espana F., Sanchez-Cuenca J., Estelles A., Gilabert J., Griffin J.H., and Heeb M.J. Quantitative immunoassay for complexes of prostate-specific antigen with α2-macroglobulin. Clin. Chem. 42 (1996) 545-550
8. Gabra B.H., Couture H., and Sirois P. Dualité fonctionnelle des récepteurs des kinines en physiopathologie. M/S 19 (2003) 1101-1110
9. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25 (2004) 276-308
10. Henze N., Olayat S., Gutman N., Zani M.N., and Courty Y. Molecular cloning and expression of an alternative hklk3 transcript coding for a variant protein of prostate-specific antigen. Cancer Res. 59 (1999) 2820-2824
11. Jacobsen S.J., and Oesterling J.E. Age-specific reference ranges for serum prostate-specific antigen levels. J. Clin. Ligang Assay 18 (1995) 93-97
12. Jia L., Choong C.S.Y., Ricciardelli C., Kim J., Tilley W.D., and Coetzee G.H. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res. 64 (2004) 2619-2626
13. Jung K., Brux B., Lein M., Rudolph B., Kristiansen G., Hauptmann S., et al. Molecular forms of prostate-specific antigen in malignant and begnin prostate tissu: biochemical and diagnostic implications. Clin. Chem. 46 (2000) 47-54
14. Lein M., Kwiatkowski M., Semjonow A., Luboldt H.J., Hammerer P., and Stephan C. A multicenter clinical trial on the use of complexed prostate-specific antigen in low prostate-specific antigen concentrations. J. Urol. 170 (2003) 1175-1179
15. Leinonen J., Zhang W.M., and Stenman U.H. Complex formation between PSA isoenzymes and protease inhibitors. J. Urol. 155 (1996) 1099-1103
16. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Petterson K., et al. Prostate-specific antigen predominantly in complex with alpha-1-antichymotrypsin. Clin. Chem. 37 (1991) 1618-1625
17. Lilja H. A kallikrein -like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76 (1985) 1899-1903
18. Lilja H. Structure, function and regulation of the enzyme activity of prostate-specific antigen. World J. Urol. 11 (1993) 188-191
19. Luderer A.A., Chen Y.T., Soriano T.F., Kramp W.J., Carlson G., Cuny C., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46 (1995) 187-194
20. Mc Cormack R.T., Rittenhouse H.G., Finlay J.A., Sokoloff R.L., Wang T.J., Wolfert R.L., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45 (1995) 729-744
21. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., et al. BPSA, a specific molecular form of free prostate-specific antigen is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
22. Noldus J., Chen Z., and Stamey T.A. Isolation and characterization of free form prostate-specific antigen (f-PSA) in sera of men with prostate cancer. J. Urol. 158 (1997) 1606-1609
23. Oesterling J.E., Chan D.W., Epstein J.I., Kimball A.W., Bruzek D.J., Rock R.C., et al. Prostate-specific antigen in the preoperative and posoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139 (1988) 766-772
24. Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145 (1991) 907-923
25. Peehl D.M. Prostate specific antigen: role and function. Cancer 75 (1995) 2021-2026
26. Rodman A.W., Duffy M.J., Hamdy F.C., Ward A.M., Patnick J., Price P.P., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur. Urol. 48 (2005) 386-399
27. Scholz M., and Strum B. Prostate specific antigen: a decade of discovery what we have learned and where we are going. J. Urol. 162 (1999) 293-306
28. Sokolof M.H., Yang X.J., Fumo M., Mhoon D., and Brendler C. Characterizing prostatic adenocarcinomas in men with a serum prostate-specific antigen level of < 4.0 ng/ml. BJU Int. 93 (2004) 499-502
29. Stamey T., Yang N., Hay A.R., MacNeal J.E., Freiha F.S., and Redwine E. Prostae-specifis antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317 (1987) 909-916
30. Steman U.H., Leinomen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51 (1991) 222-226
31. Stenman U.H., Leinomen J., Zhang W.M., and Finne P. Prostate-specific antigen. Semin. Cancer Biol. 9 (1999) 83-93
32. Stephan C., Jung K., Diamandis E.P., Rittenhouse H.G., Lein M., and Loening S.A. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59 (2002) 2-8
33. Tchetgrn M.B., and Oesterling J.E. The effect of prostatitis, urinary retention, ejaculation and ambutation on the serum prostate-specific antigen. Urol. Clin. North Am. 24 (1997) 283-291
34. Van Caugh P.J., De Nayer P., De Visher L., Sauvage P., Tambal B., Lorge F., et al. Free to total prostate-specific antigen ratio improves the discrimination between prostate cancer and prostate hyperplasia in the diagnostic gray zone of 1,8 to 10 ng/ml total PSA. Urology 48 Suppl. 6A (1996) 67-70
35. Watt K.W., Lee P.J., M'Timkulu T., Chan W.P., and Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA 83 (1986) 3166-3170
36. Wolfgang H., Berger A.P., Rogatsch H., Gschwendtner A., Steiner H., Niescher M., et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 58 (2004) 232-237
37. Woodrum D.L., Brawer M.K., Partin A.W., Catalona W.J., and Southwick P.C. Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J. Urol. 159 (1998) 5-12
38. Yang L., Wang L., Lin H.L., Kan P.Y., Xie S., Tsai M.Y., et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 305 (2003) 462-466
39. Yousef G.M., and Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22 (2001) 184-204